[Evaluation of the immunogenic and reactogenic properties of vaccine "Euvax B" in persons aged 16-18 years in different geographical zones of Russia].
The comparative evaluation of the reactogenic and immunogenic properties of vaccine "Euvax B" in adolescents aged 16-18 years was carried out in factory housing estate Lvovsky, the Podolsk district, the Moscow region, and in the Yamalo-Nenets Autonomous District (AD): in towns Salekhard, Noyabrsk, Muravlenko, in housing estate Tarko-Sale. The evaluation demonstrated that the use of this vaccine in a dose of 20 mg/ml produced no postvaccinal complications and the frequency of postvaccinal reactions was insignificant. Postvaccinal anti-HBs were detected, on the average, in protective concentrations in 98.4 +/- 1.8% of the vaccines (99.0 +/- 1.9% in the Moscow region, 97.7 +/- 3.2% in the Yamalo-Nenets AD). In most of the vaccinated adolescents high concentrations of postvacinal anti-HBs were detected: in 51.4 +/- 9.7% of the vaccinees in the Moscow region and in 89.7 +/- 6.4% in the Yamalo-Nenets AD they exceeded 1,000 I.U./lit. The conclusion was made that in the territories located in subarctic latitudes vaccinal prophylaxis against hepatitis B was safe and highly effective and have no limitations connected with the conditions of the Far North.
Kuzin
S N
SN
Zaplatnikov
A L
AL
Ibragimova
F A
FA
Skvortsova
N N
NN
Nechepurenko
L A
LA
Raengulov
B M
BM
Volova
L Iu
LIu
Popov
T M
TM
Makarenko
I V
IV
Karpova
T F
TF
Reshetniak
V V
VV
Kerivtsova
G G
GG
Varlamova
I A
IA
Kuzina
L E
LE
Malyshev
N A
NA
Zverev
V V
VV
D000293:Adolescent; D004334:Drug Administration Schedule; D005260:Female; D006509:Hepatitis B / Q000276:immunology* / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006801:Humans; D008297:Male; D012426:Russia; D014611:Vaccination; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D014761:Viral Hepatitis Vaccines